Homozygous Familial Hypercholesterolemia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Amryt Pharma, Novartis, Ultragenyx Pharma, Arrowhead

Posted on
by

Homozygous Familial Hypercholesterolemia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Amryt Pharma, Novartis, Ultragenyx Pharma, Arrowhead
DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Homozygous Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Homozygous Familial Hypercholesterolemia, historical and forecasted epidemiology as well as the Homozygous Familial Hypercholesterolemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Homozygous Familial Hypercholesterolemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Homozygous Familial Hypercholesterolemia Market Forecast

 

Some of the key facts of the Homozygous Familial Hypercholesterolemia Market Report: 

  • The Homozygous Familial Hypercholesterolemia market size was valued approximately USD 108 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • There were approximately 2,845 diagnosed prevalent HoFH cases in the 7MM in 2022. According to the report, the number of these instances would rise by 2032 at a CAGR of 0.3% from 2019 to 2032
  • About 38% of all diagnosed prevalent cases of HoFH among the 7MM were from the EU4 and the UK; this percentage is anticipated to rise during the research period
  • About 1,214 cases of HoFH resulting from LDLR gene mutations were reported in 2022. These cases were followed by 67 cases of APOB, 54 cases of other mutations (LDLRAP1, APOE, SREBP2, STAP1), and 13 cases of PCSK9 gene mutation in the US. According to DelveInsight’s estimations, these are anticipated to rise between 2023 and 2032.
  • Key Homozygous Familial Hypercholesterolemia Companies: Amryt Pharma, Novartis, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, Aegerion Pharmaceuticals, Inc., and others
  • Key Homozygous Familial Hypercholesterolemia Therapies: Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, Lomitapide, and others
  • The Homozygous Familial Hypercholesterolemia epidemiology based on mutation-specific cases analyzed that a mutation in the LDLR gene accounted for the highest diagnosed prevalent cases in the US.
  • The Homozygous Familial Hypercholesterolemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Homozygous Familial Hypercholesterolemia pipeline products will significantly revolutionize the Homozygous Familial Hypercholesterolemia market dynamics.

 

Get a Free sample for the Homozygous Familial Hypercholesterolemia Market Report 

https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market

 

Homozygous Familial Hypercholesterolemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Homozygous Familial Hypercholesterolemia Epidemiology Segmentation:

The Homozygous Familial Hypercholesterolemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Homozygous Familial Hypercholesterolemia
  • Prevalent Cases of Homozygous Familial Hypercholesterolemia by severity
  • Gender-specific Prevalence of Homozygous Familial Hypercholesterolemia
  • Diagnosed Cases of Episodic and Chronic Homozygous Familial Hypercholesterolemia

 

Download the report to understand which factors are driving Homozygous Familial Hypercholesterolemia epidemiology trends @ Homozygous Familial Hypercholesterolemia Epidemiology Forecast

 

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to get launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Homozygous Familial Hypercholesterolemia Therapies and Key Companies

  • Lomitapide: Amryt Pharma
  • Inclisiran: Novartis
  • Evinacumab: Ultragenyx Pharma
  • ARO-ANG 3 Injection: Arrowhead Pharma
  • Alirocumab: Sanofi
  • LEQVIO (inclisiran/KJX839): Novartis/ Alnylam Pharmaceutical
  • Lerodalcibep (LIB003): LIB Therapeutics
  • CER-001: Cerenis Therapeutics, SA
  • ALN-PCSSC: The Medicines Company
  • lomitapide: Aegerion Pharmaceuticals, Inc.
  • AK102: Akeso
  • AEGR-733: Aegerion Pharmaceuticals, Inc.
  • Lomitapide: Aegerion Pharmaceuticals, Inc.

 

Discover more about therapies set to grab major Homozygous Familial Hypercholesterolemia market share @ Homozygous Familial Hypercholesterolemia Treatment Market

 

Homozygous Familial Hypercholesterolemia Market Strengths

  • The clarity in disease understanding and pathogenesis have driven the development of novel pharmacological options like PCSK9inhibitors, ANGPTL3 inhibitor, and MTP inhibitor.
  • Advances in research have led to the discovery of novel molecules like siRNA and recombinant fusion protein that may offer novel options to lower LDL significantly.

 

Homozygous Familial Hypercholesterolemia Market Opportunities

  • Preclinical studies have yielded gene therapy and CRISPR-based gene editing approaches; conducting further research and clinical trials may offer curative therapy.
  • Advancements in healthcare technologies and digital health solutions can potentially enhance the early detection and personalized management of HoFH.

 

Scope of the Homozygous Familial Hypercholesterolemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Homozygous Familial Hypercholesterolemia Companies: Amryt Pharma, Novartis, Ultragenyx Pharma, Arrowhead Pharma, Sanofi, Novartis, Alnylam Pharmaceutical, LIB Therapeutics, Cerenis Therapeutics, SA, The Medicines Company, Aegerion Pharmaceuticals, Inc., Akeso, Aegerion Pharmaceuticals, Inc., and others
  • Key Homozygous Familial Hypercholesterolemia Therapies: Lomitapide, Inclisiran, Evinacumab, ARO-ANG 3 Injection, Alirocumab, LEQVIO (inclisiran/KJX839), Lerodalcibep (LIB003), CER-001, ALN-PCSSC, lomitapide, AK102, AEGR-733, Lomitapide, and others
  • Homozygous Familial Hypercholesterolemia Therapeutic Assessment: Homozygous Familial Hypercholesterolemia current marketed and Homozygous Familial Hypercholesterolemia emerging therapies
  • Homozygous Familial Hypercholesterolemia Market Dynamics: Homozygous Familial Hypercholesterolemia market drivers and Homozygous Familial Hypercholesterolemia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Homozygous Familial Hypercholesterolemia Unmet Needs, KOL’s views, Analyst’s views, Homozygous Familial Hypercholesterolemia Market Access and Reimbursement 

 

To know more about Homozygous Familial Hypercholesterolemia companies working in the treatment market, visit @ Homozygous Familial Hypercholesterolemia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Homozygous Familial Hypercholesterolemia Market Report Introduction

2. Executive Summary for Homozygous Familial Hypercholesterolemia

3. SWOT analysis of Homozygous Familial Hypercholesterolemia

4. Homozygous Familial Hypercholesterolemia Patient Share (%) Overview at a Glance

5. Homozygous Familial Hypercholesterolemia Market Overview at a Glance

6. Homozygous Familial Hypercholesterolemia Disease Background and Overview

7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Homozygous Familial Hypercholesterolemia 

9. Homozygous Familial Hypercholesterolemia Current Treatment and Medical Practices

10. Homozygous Familial Hypercholesterolemia Unmet Needs

11. Homozygous Familial Hypercholesterolemia Emerging Therapies

12. Homozygous Familial Hypercholesterolemia Market Outlook

13. Country-Wise Homozygous Familial Hypercholesterolemia Market Analysis (2019–2032)

14. Homozygous Familial Hypercholesterolemia Market Access and Reimbursement of Therapies

15. Homozygous Familial Hypercholesterolemia Market Drivers

16. Homozygous Familial Hypercholesterolemia Market Barriers

17.  Homozygous Familial Hypercholesterolemia Appendix

18. Homozygous Familial Hypercholesterolemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services